Etiology and epidemiological analysis of glaucoma-filtering bleb infections in a tertiary eye care hospital in south India

R Ramakrishnan, M Jayahar Bharathi, Devendra Maheshwari, P M T Mohideen, Mona Khurana, C Shivakumar

Purpose: To evaluate the microbial etiology and associated risk factors among patients with blebitis following trabeculectomy. Materials and Methods: A retrospective analysis of all culture-proven blebitis was performed in patients who underwent trabeculectomy between January 2004 and December 2008. A standardized form was filled out for each patient, documenting sociodemographic features and information pertaining to risk factors. Swabbing of the infected bleb surface was performed for all suspected cases and further subjected to microbiological analysis. Results: A total of 23 patients with culture-proven blebitis were treated during the study period, with a mean age of 59.2 years (59.2 ± SD: 12.8; range, 30-81 years). Duration of onset was early (<36 months) in six (26%) cases and late (>36 months) in 17 (74%) cases with a range between 15 and 144 months (mean, 82.91 months; SD: 41.89). All 23 blebs were located superiorly and of which, 21 (91%) were microcystic avascular, 1 (4%) diffuse avascular, and 1 (4%) vascular flattened. The predominant risk factor identified was bleb leak (35%; 8 of 23) followed by thin bleb (22%; 5 of 23) and blepharitis (17%; 4 of 23). Bleb leaks (100%) were recorded only in patients with late onset (>9 years) of infection (P<0.001), while the incidence of ocular surface disease (100%) occurred early (<3 years) (P<0.001). Use of topical steroids was associated frequently with cases of thin blebs (80%; 4 of 5) (P<0.001), while topical antibiotics showed bleb leaks (88%; 7 of 8) (P<0.001). Coagulase-positive staphylococci were frequently recovered from blebitis with thin blebs (71%; 5 of 7) (P=0.001), Coagulase-negative staphylococci (CoNS) with bleb leak (100%; 8 of 8) (P<0.001), Corynebacterium with blepharitis (100%; 3 of 3) (P=0.001), and Streptococci with releasable sutures (75%; 3 of 4) (P=0.001). Conclusion: Bleb leak is the principal risk factor responsible for late-onset blebitis, while early-onset blebitis could be ascribed to ocular surface diseases. Streptococci were mainly responsible for early onset of infection, while the late onset was due to CoNS.

Key words: Blebitis, bleb leak, microbiology, ocular surface diseases, risk factors

Trabeculectomy is a partial thickness glaucoma filtering surgery commonly performed to control the intraocular pressure when medical therapy or laser fails. The surgery is associated with various bleb complications, most frequently under filtration due to bleb failure, over filtration with hypotony, bleb leaks, bleb encapsulation, and bleb infection. Eyes with filtering blebs face a constant risk of infection which may occur after decades of the initial surgery. Blebitis is a microbial infection of the glaucoma filtering bleb, without any clinically apparent vitreous involvement. Blebitis after trabeculectomy is a well-known potentially dangerous complication that can lead to endophthalmitis, as the normal barriers to intraocular infections by bacteria are weakened. Variety of risk factors that are responsible for bleb infections include inferior location of the bleb site, thin-walled blebs, trauma, the use of contact lenses, bleb leaks, infectious ocular adnexal diseases, long-term use of topical steroids, systemic diseases such as diabetes, malnutrition, or compromised immune system, and the use of releasable sutures. Bleb infections are mainly caused by resident and transient flora, of which Streptococcus species was found to be the commonest cause for bleb-associated infections. Considering the importance of blebitis as a cause for intraocular infection, a proper understanding of the risk factors predisposing to blebitis and causative microbial agents are a must for early recognition and prevention of endophthalmitis. This study delineates the microbial etiology and risk factors in patients with blebitis who underwent incisional glaucoma surgery at a tertiary eye care referral center in South India.

Materials and Methods

A retrospective analysis was conducted after approval of Institutional Review Board of Aravind Eye Hospital on all case records exhibiting culture-proven blebitis among patients who had undergone trabeculectomy surgery at a tertiary eye care referral center in south India from January 2004 to December 2008. Blebitis was clinically diagnosed in patients who represented with history of redness, photophobia, conjunctival discharge, intense perilimb conjunctival congestion, opalescent bleb (white or red appearance), epithelial defects (a positive Seidel’s test) with or without anterior chamber reaction, and the absence of vitritis [Fig. 1]. The diagnosis of infectious
blebitis was confirmed by the significant microbial growth in swab cultures obtained from bleb surfaces. Cases of iritis, purulent conjunctivitis, or ulcerative blepharitis without bleb infiltration were excluded. Seidel's test was performed in all the clinically suspected cases before being subjected to microbiological evaluation. The data protocol followed for each patient with blebitis comprised of documentation of sociodemographic features, associated clinical features, duration of symptoms, duration of surgery, predisposing risk factors and associated ocular conditions, systemic diseases, and information pertaining to the history of medical therapy. After detailed oculomacular examinations, bleb cultures were collected from bleb surfaces using sterile swab pre-moistened with brain heart infusion broth and were subjected to microbiological analysis based on the standard protocols. Swab cultures were made on blood agar (supplemented with 5% defibrinated sheep blood), chocolate agar, and S. aureus dextrose agar, inoculated into thioglycolate medium and brain heart infusion broth. Smears were also made from swabs for direct microscopic identification by Gram's stain.

The inoculated blood agar, chocolate agar, thioglycolate broth, and brain heart infusion broth were incubated at 37°C under 5% CO₂, examined daily, and discarded at 7 days if growth was absent. The inoculated S. aureus dextrose agar plates were incubated at 27°C under biochemical oxygen demand, examined daily, and were discarded at 3 weeks if there was no growth. Microbial cultures were considered significant if growth of the same organism was demonstrated on more than one solid phase medium, and/or if growth of one medium was consistent with direct microscopy findings (that is, appropriate staining and morphology with Gram stain). The isolated bacterial strains were identified up to species level by using standard biochemical tests. The in vitro susceptibility testing was performed by Kirby-Bauer disc diffusion method and interpreted using Clinical and Laboratory Standards Institute serum standards. The antibacterial agents used were constantly tested for their consistency in efficacy against standard ATCC (American Type Culture Collection) bacteria (Staphylococcus aureus ATCC 25923, Streptococcus pneumoniae ATCC 49619, Haemophilus influenzae ATCC 49241, Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922) as a general quality control laboratory procedure.

Statistical software STATA version 8.1 (Stata Corporation LP, College Station, Texas, USA) was used to carry out all analyses. Data are expressed in terms of mean ± standard deviation for continuous variables; number (%) for categorical variables. Pearson’s Chi-square test (Yates Corrected) was used to determine the association between the predisposing risk factors identified and the isolated microbial etiology found responsible for the development of blebitis, and also to determine the significance in the onset of infection and predisposing risk factors identified. \( P < 0.05 \) was considered statistically significant.

**Results**

During the study period of five years, a total of 51 patients with clinical diagnosis of blebitis having a history of incisional glaucoma surgery were evaluated and underwent microbiological evaluation at our institute. Of the 51 patients, 23 eyes of 23 patients showed significant bacterial growth in microbial culture. All the trabeculectomies were performed by a senior glaucoma consultant of the institute using standard surgical procedures; 19 (83%) were males and four (17%) were females. Their ages ranged from 30 to 81 years, with a mean of 59.17 ± SD: 12.75. Most of them (91%) had trabeculectomy for primary open-angle glaucoma. The mean duration between the trabeculectomy performed and the onset of blebitis was 82.9 months (SD: 41.9; range: 15 to 144 months). Twelve (52%) patients had used topical steroids and eight (35%) had used topical antibiotics for more than 6 months beyond the postoperative period. Apart from patients with blebitis, ocular adnexal diseases were noted in seven (30%), nasolacrimal duct obstruction in three (13%), and systemic diseases in six (26%) patients. Most (91.3%) of the blebs were functioning as avascular [Table 1].

Factors predisposing to blebitis in all the 23 patients were classified into primary risk factors which directly influenced the infection and secondary risk factors that in one way or the other influenced blebitis. In all patients, more than one risk factor predisposed to blebitis [Table 2]. The most common primary and secondary risk factors encountered were bleb leak (35%; 8 of 23) and the use of topical steroids (12, 52%), respectively. Patients with blebitis-associated bleb leaks (100%; 8 of 8 bleb leaks) were recorded only in cases with late onset of infections (≥ 9 years) (89%; 8 of 9 late onset of infections) \( P < 0.001 \), while those with ocular adnexal diseases (blepharitis, conjunctivitis, and dacroycystitis) (86%; 6 of 7 ocular surface infections) were seen exclusively during the early onset of infection (≤ 3 years) (100%; 6 of 6 early onset of infections) \( P < 0.001 \). Blebitis associated with thin blebs were exhibited among patients using topical steroids continuously (80%; 4 of 5 thin blebs) \( P < 0.001 \), while the use of topical antibiotics too was significantly noted among patients with blebitis associated with bleb leaks (88%; 7 of 8 bleb leaks) \( P < 0.001 \).

All the 23 culture swabs obtained from bleb surfaces of patients showed bacterial growth. The predominant bacterial isolate recovered in this study was *Staphylococcus* species (65%; 15 of 23), of which *Staphylococcus aureus* (26%; 6 of 23) was frequently isolated. All three strains of *Corynebacterium xerosis* were recovered from blebitis associated with blepharitis (100%)
Table 1: Demographic and clinical characteristics of patients with culture-proven blebitis treated at tertiary eye care center in South India

| Characteristics                               | No. of eyes (%) |
|-----------------------------------------------|-----------------|
| **Age**                                       |                 |
| Mean ± SD                                      | 59.17 ± 12.75   |
| Range                                         | 30 - 81 years   |
| 30 - 35 years                                 | 2 (9)           |
| 36 - 40 years                                 | 1 (4)           |
| 41 - 45 years                                 | 1 (4)           |
| 46 - 50 years                                 | 1 (4)           |
| 51 - 55 years                                 | 3 (13)          |
| 56 - 60 years                                 | 2 (9)           |
| 61 - 65 years                                 | 3 (22)          |
| 66 - 70 years                                 | 5 (22)          |
| 71 - 75 years                                 | 2 (9)           |
| 76 - 80 years                                 | 0               |
| 81 - 85 years                                 | 1 (4)           |
| **Sex**                                       |                 |
| Male                                          | 19 (83)         |
| Female                                        | 4 (17)          |
| **Eye**                                       |                 |
| Right                                         | 10 (43)         |
| Left                                          | 13 (57)         |
| **Glaucoma diagnosis**                        |                 |
| Primary glaucoma                              | 21 (91)         |
| Primary open angle glaucoma                   | 2 (9)           |
| **Location of filter**                        |                 |
| Superior 12 'O clock                          | 23 (100)        |
| **Duration between trabeculectomy performed and onset of symptoms** |                 |
| Mean ± SD                                     | 82.91 ± 41.89   |
| Range                                         | 15 to 144 months|
| <24 months                                    | 1 (4)           |
| 24 - 36 months                                | 5 (22)          |
| 37 - 48 months                                | 1 (4)           |
| 49 - 60 months                                | 1 (4)           |
| 61 - 72 months                                | 1 (4)           |
| 73 - 84 months                                | 1 (4)           |
| 85 - 96 months                                | 3 (13)          |
| 97 - 108 months                               | 3 (13)          |
| 109 - 120 months                              | 2 (9)           |
| 120 - 132 months                              | 2 (9)           |
| 133 - 144 months                              | 3 (13)          |
| **Conjunctival flap**                         |                 |
| Limbal based                                  | 2 (9)           |
| Fornix based                                  | 21 (91)         |
| **Type of bleb**                              |                 |
| Functioning                                   |                 |
| Microcystic avascular                         | 21 (91)         |
| Diffuse avascular                             | 1 (4)           |
| Non-functioning                               |                 |
| Vascularized                                  | 1 (4)           |
| **Antimetabolites**                           |                 |
| Mitomycin-C (0.02% for 2 minutes)             | 23 (100)        |
| 5-FU                                          | 0               |
| **Type of surgery**                           |                 |
| Trabeculectomy alone                          | 21 (91)         |
| Trabeculectomy with phacoemulsification and posterior capsular IOL implantation | 2 (9) |
| **Systemic diseases**                         |                 |
| Hypertension                                  | 2 (9)           |
| Diabetic mellitus                             | 2 (9)           |
| Asmatic                                       | 2 (9)           |
| **Use of topical steroids**                   |                 |
| Intermittent use                              | 8 (35)          |
| Continuous and chronic use                    | 4 (17)          |
| **Use antibiotics**                           |                 |
| Intermittent use                              | 7 (30)          |
| Continuous and chronic use                    | 1 (4)           |
| **Nasolacrimal duct potency**                 |                 |
| Free                                          | 20 (87)         |
| Not free with clear fluid                     | 2 (9)           |
| Not free with pus and mucus                   | 1 (4)           |
| **Early postoperative complication if any**   |                 |
| Flat anterior chamber                         | 1 (4)           |
| Early wound leak                              | 0               |
| **Bleb leak**                                 |                 |
| Early onset of bleb leak (<9 years)           | 0               |
| Late onset of bleb leak (≥ 9 years)           | 8 (35)          |
| **Status of the bleb walls on presentation**  |                 |
| Thin wall                                     | 5 (22%)         |
| **Type of sutures**                           |                 |
| Releasable sutures                            | 3 (13)          |
| Fixed scleral flap                            | 20 (87)         |
| **Ocular surface diseases**                   |                 |
| Blepharitis                                   | 4 (17)          |
| Conjunctivitis                                | 2 (9)           |
| Dacryocystitis                                | 1 (4)           |

(P = 0.001). More number of *Streptococcus* species were isolated from blebitis associated with releasable sutures (75%; 3 of 4 total *Streptococcus* isolates) than any other ocular conditions (25%; 1 of 4) (P = 0.001). Coagulase-positive staphylococci (CoPS) were recovered significantly from blebitis associated with thin bleb (71%; 5 of 7 total CoPS) than in cases with any other ocular conditions (29%; 2 of 7) (P = 0.001). All the coagulase-negative staphylococci (CoNS) were recovered only from blebitis associated with bleb leak (100%; 8 of 8) (P<0.001). All the three *Streptococcus pneumoniae* (100%) were recovered only from blebitis associated with obstruction of nasolacrimal duct (P = 0.001) [Table 3]. All the CoNS recovered were from blebitis that occurred during the late postoperative period, > 8 year (P<0.001), whereas the bacterial isolates that were recovered from blebitis associated with eye lid infections represented *C. xerosis* to be significantly associated with early postoperative period (P<0.001) [Table 4].

Viewing the antibacterial susceptibility nature, it was extrapolated that the large percentage of bacterial isolates were
Table 2: Association between the risk factors identified and duration between the trabeculectomy performed and onset of the infections in 23 patients with culture-proven blebitis presented at tertiary eye care referral center in south India

| Name of risk factors identified | Total number of cases (%) | Duration between the trabeculectomy performed and onset of the infection in months |
|--------------------------------|---------------------------|----------------------------------------------------------------------------------|
|                                |                           | 15  | 24  | 26  | 30  | 36  | 40  | 56  | 72  | 80  | 86  | 96  | 100 | 108 | 110 | 115 | 122 | 130 | 133 | 144 |
| Primary risk factors           |                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Total number of cases (%)      | 23 (100)                  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Blepharitis                    | 4 (17)                    | 1 (25) | 1 (25) | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Conjunctivitis                 | 2 (9)                     | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Bleb leak                      | 8 (35)                    | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Thin bleb                      | 5 (22)                    | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Releasable sutures             | 3 (13)                    | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Dacryocystitis                 | 1 (4)                     | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Secondary possible risk factors|                           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Total number of cases (%)      | 23 (100)                  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Nasolacrimal duct obstruction  | 3 (13)                    | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Continuous and chronic use of topical antibiotics | 1 (4) | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Intermittent use of topical antibiotics | 7 (30) | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Continuous and chronic use of topical steroids | 4 (17) | 1 (25) | 1 (25) |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Intermittent use of topical steroids | 8 (35) | 0 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
Table 3: Association between risk factors identified and the bacterial species recovered from eyes with blebitis (n = 23) treated between January 2005 and December 2008 at tertiary eye care referral center in South India

| Name of the bacterial species isolated | Total number of isolates (%) | Primary risk factors associated with blebitis Number (%) | Secondary factors associated with blebitis. Number (%) |
|---------------------------------------|-----------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                       |                             | Blepharitis Conjunctivitis Bleb leak Thin bleb Relesable sutures Dacryocystitis | Total number of isolates (%), Nasolacrimal duct obstruction Continuous and chronic use of topical antibiotics Intermittent use of topical antibiotics Continuous and chronic use of topical steroids |
| Haemophilus influenzae                 | 1 (4)                       | 0 1(100) 0 0 0 0 0 0 1 (4) 0 0 0 0 | 1 (4) 0 0 0 0 1 (100) 0 |
| Corynebacterium xerosis               | 3 (13)                      | 3 (100) 0 0 0 0 0 0 3 (13) 0 0 0 2 (67) 1 (33) |
| Streptococcus species                 | 4 (17)                      | 0 0 0 0 3 (75) 1 (25) 4 (170) 3 (75) 0 0 0 1 (25) |
| S. pneumoniae                         | 3 (13)                      | 0 0 0 0 2 (67) 1 (33) 3 (13) 3 (100) 0 0 0 0 |
| S. viridans group                     | 1 (4)                       | 0 0 0 0 1 (100) 0 1 (4) 0 0 0 0 1 (100) |
| Staphylococcus species                | 15 (65)                     | 1 (7) 1 (7) 8 (53) 5 (33) 15 (65) 0 1 (7) 7 (47) 1 (7) 6 (40) |
| Coagulase positive                    | 7 (30)                      | 1 (17) 1 (15) 0 5 (71) 0 7 (30) 0 0 1 1 4 |
| S. aureus                             | 6 (26)                      | 1 (17) 1 (17) 0 4 (67) 0 6 (26) 0 0 1 1 4 |
| S. intermedius                        | 1 (4)                       | 0 0 0 1 (100) 0 1 (4) 0 0 0 0 1 |
| Coagulase negative                    | 8 (35)                      | 0 0 8 (100) 0 0 0 8 (35) 0 1 6 0 1 |
| S. epidermidis                        | 2 (9)                       | 0 0 2 (100) 0 0 2 (9) 0 0 2 (100) 0 0 |
| S. hominis                            | 3 (13)                      | 0 0 3 (100) 0 0 3 (13) 0 1 (33) 1 (33) 0 1 (33) |
| S. caprae                             | 2 (9)                       | 0 0 2 (100) 0 0 2 (9) 0 0 2 (100) 0 0 |
| S. saccharolyticus                    | 1 (4)                       | 0 0 1 (100) 0 0 1 (4) 0 0 1 (100) 0 0 |
| Total no. of isolates (%)             | 23 (100)                    | 4 (17) 2 (9) 8 (35) 5 (22) 3 (13) 1 (4) 23 (100) 3 (13) 1 (4) 7 (30) 4 (17) 8 (35) |
Table 4: Association between the bacterial pathogens isolated and duration of onset of the infection in 23 patients with culture-proven blebitis presented at tertiary eye care referral center in south India

| Name of risk factors identified | Total number of cases (%) | Duration between the trabeculectomy performed and onset of the infection in months |
|--------------------------------|---------------------------|----------------------------------------------------------------------------------|
|                                |                           | 15  | 24  | 26  | 30  | 36  | 56  | 72  | 80  | 86  | 96  | 100 | 108 | 110 | 115 | 122 | 130 | 133 | 144 |
| **Haemophilus influenzae**     | 1 (4)                     | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 0   | 0   | 0   | 0   | 0   | 0   |
| **Corynebacterium xerosis**   | 3 (13)                    | 1 (33) | 1 (33) | 0   | 0   | 1 (33) | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| **Streptococcus pneumoniae**  | 4 (17)                    | 0   | 0   | 0   | 0   | 1 (25) | 1 (25) | 1 (25) | 0   | 1 (25) | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| **S. viridans group**         | 3 (13)                    | 0   | 0   | 0   | 0   | 1 (33) | 1 (33) | 1 (33) | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| **Staphylococcus species**    | 15 (65)                   | 0   | 0   | 1 (7) | 1 (7) | 0   | 0   | 1 (7) | 0   | 1 (7) | 2 (13) | 1 (7) | 1 (7) | 1 (7) | 1 (7) | 1 (7) | 1 (7) | 1 (7) | 1 (7) | 1 (7) | 2 (13) |
| **Coagulase positive**        | 7 (30)                    | 0   | 0   | 1 (14) | 1 (14) | 0   | 0   | 1 (14) | 0   | 1 (14) | 2 (29) | 1 (14) | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| **S. aureus**                 | 6 (26)                    | 0   | 0   | 1 (17) | 1 (17) | 1 (17) | 0   | 1 (17) | 1 (17) | 1 (17) | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| **S. intermedius**            | 1 (4%)                    | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| **Coagulase negative**        | 8 (35)                    | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1 (13) | 1 (13) | 1 (13) | 1 (13) | 1 (13) | 1 (13) | 1 (13) | 2 (25) |
| **S. epidermidis**            | 2 (9)                     | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1 (50) | 0   | 0   | 0   | 0   |
| **S. hominis**                | 3 (13)                    | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1 (33) | 1 (33) | 0   | 1 (33) |
| **S. caprae**                 | 2 (9)                     | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| **S. saccharolyticus**        | 1 (4)                     | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| **Total number (%)**          | 23 (100)                  | 1 (4) | 1 (4) | 1 (4) | 1 (4) | 2 (9) | 1 (4) | 1 (4) | 1 (4) | 1 (4) | 1 (4) | 1 (4) | 2 (9) | 1 (4) | 2 (9) | 1 (4) | 1 (4) | 1 (4) | 1 (4) | 2 (9) |
susceptible to chloramphenicol (100%) followed by vancomycin (97%) and cefazolin (96%) [Table 5]. Staphylococcus spp. showed 100% susceptibility against chloramphenicol, vancomycin, cefazolin, amikacin, tobramycin, and gentamicin, whereas Streptococci portrayed 100% susceptibility against cefazolin, cefotaxime, chloramphenicol, and vancomycin. Corynebacterium spp. exhibited a higher susceptibility against chloramphenicol, vancomycin, cefazolin, and ofloxacin.

Discussion

Blebitis is infrequent, but if left untreated, may lead on to endophthalmitis after glaucoma filtering surgery. Blebitis is a mucopurulent infiltrate that is seen within the bleb along with or without anterior segment inflammation, whereas endophthalmitis is associated with the evidence of inflammation of the vitreous.[11] Literature reviews indicate that the normal flora of eyelids and conjunctiva are responsible for the development of blebitis. The present study demonstrates the role of resident or transient ocular bacterial flora with the predominance of Staphylococcus species (65%) in causing blebitis in trabeculectomized eyes. Several studies have reported Staphylococcus species to be the most common organism responsible for blebitis.[12,13] In addition, Staphylococcus species, especially CoNS, have been framed to be the common cause for the early onset of bleb-associated endophthalmitis which are similar to that of acute-onset endophthalmitis after cataract surgery.[15,16]

The analysis on the association between bacterial etiology isolated and the duration of the onset of disease revealed the significant association of CoNS with the late onset of blebitis (>3 years) due to bleb leaks. Staphylococci neither produce exotoxins nor do they have the ability to penetrate intact conjunctiva.[17] However, it is possible that higher incidences of Staphylococcus species among blebitis with bleb leaks may allow less virulent bacteria to easily enter bleb and intraocular spaces.[18] Bacterial isolates recovered from blebitis associated with ocular surface diseases such as C. xerosis, S. aureus, and S. pneumoniae were recovered significantly during the early onset of infection (≤3 years). Blepharitis, conjunctivitis, and dacryocystitis are the most important sources for infection of blebs and the association of C. xerosis in blepharitis cases, S. aureus in conjunctivitis, and S. pneumoniae in dacryocystitis demonstrates the source from ocular surfaces. It has been suggested that blebs associated with ocular surface infectious diseases become more susceptible to infection with the etiology of surface infection registering greater microbial load from infected sites. Higher prevalence of Streptococcus species during the late onset of bleb-associated endophthalmitis have also been reported.[5,9,18] Whereas, in the present study, the prevalence of Streptococcus species accounting to 75% in the early onset group of blebitis were associated with dacryocystitis and releasable sutures in those nasolacrimal ducts were obstructed. Thus, it seems that the higher prevalence of Streptococcus species in the early onset of blebitis is due to the presence of nasolacrimal duct obstruction in these cases.

The most common risk factor identified was bleb leaks (35%) and its association was found to be highly significant with the late onset of blebitis (≥9 years). Higher incidence of bleb leak among eyes with bleb-related infection have been documented.[15] It has been outlined that in bleb infections associated with bleb leaks, the bacterial pathogens itself create a hole in the bleb first before entering the eye and causing infection, while the other school of thought stresses that once a hole is created, the pathogenic bacteria in the tear film invades and causes infection.[16,17] It needs to be emphasized that the tear film directly has an access to the anterior chamber through leaking filtering bleb and hence, it provides an uninterrupted passage way into the anterior chamber for infectious organisms.[18] In addition, most of the bleb leak cases had used topical antibiotics beyond the prescribed period following trabeculectomy. The use of prophylactic topical antibiotics beyond the prescribed postoperative periods have been reported and their strong association with an increased risk of bleb-related infections have been lucidly portrayed.[20,21,23] Next to bleb leaks, thin blebs too were frequently encountered, especially among blebitis after 6 to 8 years of the postoperative period from which CoPS were isolated, whose association was highly significant. In addition, 80% of the cases examined had used topical corticosteroids. Probably, the chronic use of topical corticosteroids in eyes that have undergone trabeculectomy can lead to the thinning of conjunctiva, and later become susceptible to highly virulent bacterial strains like S. aureus. The indiscriminate use of topical corticosteroids can damage the ocular tissues and lead to the increased risk of infection.[24]

All cases of blebitis associated with releasable sutures were caused by Streptococcus sp. and the association was highly significant. In addition, 67% of the releasable suture cases had nasolacrimal duct obstruction as secondary risk factors, with the association of Streptococcal infection in blebs further confirming the source of infection and Streptococci as the most common etiological agent. Since most bacterial isolates recovered in this study were the normal flora of conjunctiva and eyelids, it is important for an ophthalmologist to be aware the risk of infection of blebs by normal bacterial flora in post of trabeculectomy eyes.

In the present study, chloramphenicol is appeared to be 100% effective against the bacterial isolates recovered from blebitis. Chloramphenicol is a broad-spectrum bacteriostatic antibiotic widely used against Gram-positive and Gram-negative bacterial ocular infections.[25] Although chloramphenicol is an effective antibiotic, its use has been implicated in systemic hemotoxicity[26] and fatal aplastic anemia.[27] Vancomycin is a glycopeptide exhibiting greatest potency against blebitis pathogens, except H. influenzae. Similarly, the first-generation cephalosporin and cefazolin also revealed greatest activity here against the Gram-positive bacteria. However, vancomycin and cefazolin are not available as topical formulations and must be prepared for topical usage.

Aminoglycosides, especially amikacin and tobramycin, also depicted good activity against Staphylococcus, Corynebacterium, and Haemophilus species, whereas it was inactive against Streptococci. Among fluoroquinolones, gatifloxacin alone portrayed inhibition, with 74% of bacterial isolates showing good activity. One possible explanation for this could be attributed to the frequent and routine use of fluoroquinolones in ophthalmological preoperative preparations and postoperative management leading to antibiotic resistance among bacterial pathogens. It is of prime significance to note that fluoroquinolones resistance among streptococci and CoNS are common in ocular surface infections.[28] The current analysis
Table 5: *In vitro* antibacterial susceptibilities of bacterial isolates recovered from blebitis against commonly used antibacterial agents

| Name of bacterial isolates | No. of tested isolates | Amikacin | Tobramycin | Gentamicin | Cefazolin | Cefotaxime | Ceftriaxone | Norfloxacin | Ciprofloxacin | Ofloxacin | Levofloxacin | Gatifloxacin | Moxifloxacin | Chloramphenicol | Vancocin |
|---------------------------|------------------------|----------|------------|------------|-----------|------------|-------------|-------------|---------------|-----------|--------------|--------------|--------------|-----------------|---------|
| *Staphylococcus* species  |                        |          |            |            |           |            |             |             |               |           |              |              |              |                  |         |
| Coagulase-positive        | 15                     | 15/15 (100) | 15/15 (100) | 15/15 (100) | 12/15 (80) | 11/15 (73) | 7/15 (47)  | 9/15 (60)   | 7/15 (47)     | 7/15 (47) | 13/15 (87)   | 10/15 (67)   | 15/15 (100)  | 15/15 (100)    |         |
| *S. aureus*               | 7                      | 7/7 (100)  | 7/7 (100)  | 7/7 (100)  | 4/7 (57)   | 4/7 (57)   | 3/7 (43)   | 4/7 (57)   | 3/7 (43)       | 4/7 (57) | 6/7 (86)     | 4/7 (57)     | 7/7 (100)    | 77 (100)        |         |
| *S. intermedius*          | 6                      | 6/6 (100)  | 6/6 (100)  | 6/6 (100)  | 4/6 (67)   | 4/6 (67)   | 3/6 (50)   | 4/6 (67)   | 3/6 (50)       | 4/6 (67) | 5/6 (83)     | 4/6 (67)     | 6/6 (100)    | 6/6 (100)       |         |
| Coagulase-negative        | 1                      | 1/1 (100)  | 1/1 (100)  | 1/1 (100)  | 0/1 (0)    | 0/1 (0)    | 0/1 (0)    | 0/1 (0)    | 0/1 (0)        | 0/1 (0) | 1/1 (100)    | 0/1 (0)      | 1/1 (100)    | 1/1 (100)       |         |
| *S. epidermidis*          | 8                      | 8/8 (100)  | 8/8 (100)  | 8/8 (100)  | 7/8 (88)   | 4/8 (50)   | 5/8 (63)   | 4/8 (50)   | 4/8 (50)       | 7/8 (88) | 6/8 (75)     | 8/8 (100)    | 8/8 (100)    | 8/8 (100)       |         |
| *S. hominis*              | 3                      | 3/3 (100)  | 3/3 (100)  | 3/3 (100)  | 3/3 (100)  | 2/3 (67)   | 1/3 (33)   | 2/3 (67)   | 1/3 (33)       | 3/3 (100) | 3/3 (100)    | 3/3 (100)    | 3/3 (100)    | 3/3 (100)       |         |
| *S. caprae*               | 2                      | 2/2 (100)  | 2/2 (100)  | 2/2 (100)  | 2/2 (100)  | 2/2 (100)  | 2/2 (100)  | 2/2 (100)  | 2/2 (100)      | 2/2 (100) | 2/2 (100)    | 2/2 (100)    | 2/2 (100)    | 2/2 (100)       |         |
| *S. saccharolyticus*      | 1                      | 1/1 (100)  | 1/1 (100)  | 1/1 (100)  | 1/1 (100)  | 1/1 (100)  | 0/1 (0)    | 0/1 (0)    | 0/1 (0)        | 1/1 (100) | 1/1 (100)    | 1/1 (100)    | 1/1 (100)    | 1/1 (100)       |         |
| *Streptococcus* species   | 4                      | 0/4 (0)   | 0/4 (0)    | 0/4 (0)    | 4/4 (100)  | 3/4 (75)   | 3/4 (75)   | 3/4 (75)   | 3/4 (75)       | 3/4 (75) | 3/4 (75)     | 3/4 (75)     | 3/4 (75)    | 4/4 (100)       |         |
| *S. pneumoniae*           | 3                      | 0/3 (0)   | 0/3 (0)    | 0/3 (0)    | 3/3 (100)  | 3/3 (100)  | 3/3 (100)  | 3/3 (100)  | 3/3 (100)      | 3/3 (100) | 3/3 (100)    | 3/3 (100)    | 3/3 (100)    | 3/3 (100)       |         |
| *S. viridans* group       | 1                      | 0/1 (0)   | 0/1 (0)    | 0/1 (0)    | 0/1 (0)    | 0/1 (0)    | 0/1 (0)    | 0/1 (0)    | 0/1 (0)        | 0/1 (0) | 0/1 (0)      | 0/1 (0)      | 0/1 (0)     | 1/1 (100)       |         |
| *Corynebacterium* xerosis| 3                      | 3/3 (100) | 1/3 (33)   | 0/3 (0)    | 3/3 (100)  | 1/3 (33)   | 0/3 (0)    | 1/3 (33)   | 0/3 (0)        | 3/3 (100) | 0/3 (0)      | 0/3 (0)      | 0/3 (0)     | 3/3 (100)       |         |
| *Haemophilus influenzae*  | 1                      | 1/1 (100) | 1/1 (100)  | 1/1 (100)  | 0/1 (0)    | 1/1 (100)  | 1/1 (100)  | 1/1 (100)  | 1/1 (100)      | 0/1 (0) | 0/1 (0)      | 0/1 (0)      | 0/1 (0)     | 0/1 (100)       |         |
| Total no. of susceptible/total number tested (%) | 23 | 19/23 (83) | 17/23 (74) | 16/23 (70) | 22/23 (96) | 18/23 (78) | 15/23 (65) | 12/23 (52) | 13/23 (57)      | 14/23 (61) | 11/23 (48)    | 16/23 (74)    | 13/23 (57)   | 22/23 (97)      |
on the *in vitro* antibacterial susceptibilities lucidly reveal and emphasize that the predominant etiology of blebitis being Gram-positive bacteria, chloramphenicol, vancomycin, and cefazolin are proven choices for treating post-trabeculectomy infections and could be advocated. In conclusion, bleb leak is the principal risk factor for blebitis of late onset, while the early-onset blebitis could be associated with ocular surface diseases. *Staphylococcus* species are the predominant bacterial pathogen recovered in this study, and are mainly associated with late onset, especially CoNS, while the early onset was due to *Streptococcus* species. Since Gram-positive bacteria (96%) are found to be the predominant cause for blebitis in this study; chloramphenicol, vancomycin, and cefazolin are proven choices of antibiotic for treating post-trabeculectomy infections.

References

1. Poulsen EJ, Allingham RR. Characteristics and risk factors of infections after glaucoma filtering surgery. J Glaucoma 2000;9:438-43.
2. Soltau JB, Rothman RF, Budenz DL, Greenfield DS, Feuer W, Liebmann JM, *et al*. Risk factors for glaucoma filtering bleb infections. Arch Ophthalmol 2000;118:338-42.
3. Kangas TA, Greenfield DS, Flynn HW, Parrish RK, Palmberg P. Delayed-onset endophthalmitis associated with conjunctival filtering blebs. Ophthalmology 1997;104:746-52.
4. Greenfield DS, Suler IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996;114:943-9.
5. Leng T, Miller D, Flynn HW Jr, Jacobs DJ, Gedde SJ. Delayed-onset bleb-associated endophthalmitis (1996-2008): Causative organisms and visual acuity outcomes. Retina 2011;31:344-52.
6. Al-Turki TA, Al-Shahwan S, Al-Mezaine HS, Kangave D, Abu El-Arar AM. Microbiology and visual outcome of bleb-associated endophthalmitis. Ocul Immunol Inflamm 2010;18:121-6.
7. Allingham RR, Damji KF, Freedman S, Moroi SE, Shafranov G, Shield MB. Shield’s Text book of glaucoma: Filtering surgery, Chapter 40. 5th ed. Philadelphia: Lippincott William and Wilkins, JB; 2005. p. 568-609.
8. Wilhelmus KR, Liesegang TJ, Osato MS, Jones DB. Cumitech 13A, Laboratory Diagnosis of Ocular Infections. Washington DC: American Society for Microbiology; 1994.
9. Barrow GI, Feltham RKA. Cowan and Steele’s Manual for the identification of medical bacteria. 3rd edition. Cambridge: University Press; 1993.
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility test. The National Committee For Clinical Laboratory Standards. 1993;13:1-31.
11. Brown RH, Yang LH, Walker SD, Lynch MG, Martinez LA, Wilson LA. Treatment of bleb infection after glaucoma surgery. Arch Ophthalmol 1994;112:57-61.
12. Waheed S, Ritterband DC, Greenfield DS, Liebmann JM, Seedor JA, Ritch R. New pattern of infecting organisms in late bleb-related endophthalmitis: A ten year review. Eye 1998;12:910-5.
13. Chen FP, Gedde SJ, Budenz DL, Parrish RK. Out-patient treatment of bleb infection. Arch Ophthalmol 1997;115:1124-8.
14. Ciulla TA, Beck AD, Topping TM, Baker AS. Blebitis, early endophthalmitis and late endophthalmitis after glaucoma filtering surgery. Ophthalmology 1997;104:986-95.
15. Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol 1996;122:830-46.
16. Ramakrishnan R, Bharathi MJ, Shivkumar C, Mittal S, Meenakshi R, Khadeer MA, *et al*. Microbiological profile of culture-proven cases of exogenous and endogenous endophthalmitis: A 10-year retrospective study. Eye 2009;23:945-56.
17. Prasad N, Latina MA. Blebitis and endophthalmitis after glaucoma filtering surgery. Int Ophthalmol Clin 2007;47:85-97.
18. Beck AD, Grossniklaus HE, Hubbard B, Saperstein D, Haupert CL, Margo CE. Pathologic findings in late endophthalmitis after glaucoma filtering surgery. Ophthalmology 2000;107:2111-4.
19. Song A, Scott IU, Flynn HW, Budenz DL. Delayed-onset bleb-associated endophthalmitis. Clinical features and visual acuity outcomes. Ophthalmology 2002;109:985-91.
20. Jampel HD, Quigley HA, Kerrigan-Baumrind LA, Melia BM, Friedman D, Barron Y, *et al*. Risk factors for late-onset infection following glaucoma filtering surgery. Arch Ophthalmol 2001;119:1001-8.
21. Mac I, Soltau JB. Glaucoma-filtering bleb infections. Curr Opin Ophthalmol 2003;14:91-4.
22. Gollamudi SR, Hodapp EA, Cubillas A, Culbertson WW. Photographically documented access of tear film to the anterior chamber through a leaky filtering bleb. Arch Ophthalmol 1993;111:394-5.
23. Wand M, Quintilian R, Robinson A. Antibiotic prophylaxis in eyes with filtration blebs: Survey of glaucoma specialists, microbiologic study, and recommendations. J Glaucoma 1995;4:103-9.
24. Reynolds AC, Skytta GL, Monlux R, Johnson J. Management of blebitis by members of the American glaucoma society: A survey. J Glaucoma 2001;10:340-7.
25. Kowalski RP, Kriencak LM, Romanowski. Infectious disease: Changing antibiotic susceptibility. Ophthalmol Clin N Am 2003;16:1-9.
26. Pierre-Yves R, Jean-Paul A. Comparative review of topical ophthalmic antibacterial preparation. Drugs 2001;61:175-85.
27. Fraunfelder FT, Bagby GC, Kelly DJ. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982:93:356-60.
28. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: A 5-year review. Ophthalmology 1999;106:1313-8.

Source of Support: Aravind Eye Care System. Conflict of Interest: None declared.
